Living network meta-analysis was feasible when considering the pace of evidence generation.

Objectives: The aim of the study was to assess the feasibility of living network meta-analysis (NMA) taking into account the pace of evidence generation across different medical areas.

Study Design And Setting: We performed a systematic review to identify published NMAs. For each NMA, we calculated the cumulative number of new trials.

Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.

Background: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on this topic is increasing. Our objective was to assess the comparative effectiveness and tolerability of all second-line treatments for advanced NSCLC with wild-type or unknown status for EGFR by a systematic review and network meta-analysis.

Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials.

Background: Ranking of interventions is one of the most appealing elements of network meta-analysis. There is, however, little evidence about the reliability of these rankings.

Purpose: To empirically evaluate the extent of uncertainty in intervention rankings from network meta-analysis.